Skip to main content
. 2009 Dec;4(12):1954–1961. doi: 10.2215/CJN.04100609

Table 5.

Sensitivity analysis evaluating inflation-adjusted PMPM costs in two patient follow-up cohorts in 2001 and three patient cohorts in 2004

Inflation-Adjusted Costs ($)
Inpatient Outpatient SNF Other Phosphate Binders
 Total
AWP WAC AWP WAC
2001
    Cohort
        Randomized (90 da)
            Calcium 1660 3533 106 164 27 22 5490 5485
            Sevelamer 1476 3530 79 163 308 246 5556 5494
            Difference 184 3 27 1 −281 −224 −66 −9
            Randomized (end of 2004b)
            Calcium 1727 3544 120 175 27 21 5593 5587
            Sevelamer 1591 3509 87 162 304 243 5653 5592
            Difference 136 35 33 13 −277 −222 −60 −5
2004
    Cohort
        Dosed (90 da)
            Calcium 1841 3944 116 183 42 33 6125 6116
            Sevelamer 1636 3959 84 180 371 297 6231 6157
            Difference 205 -16 32 2 −329 −264 −106 −41
            Randomized (90 da)
        Calcium 1859 3957 117 180 47 37 6160 6150
            Sevelamer 1653 3954 87 179 376 301 6249 6174
            Difference 206 3 30 1 −329 −264 −89 −24
        Randomized (end of 2004b)
            Calcium 1934 3969 132 193 45 36 6273 6264
            Sevelamer 1782 3930 96 178 370 296 6356 6282
            Difference 152 39 36 14 −325 −260 −83 −18

Drug costs were estimated costs and were not directly collected in the study.

SNF, skilled nursing facility.

a

Early-termination patients followed an additional 90 d after early termination.

b

Early-termination patients followed to the end of 2004.